Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
4.3
Journals
Pharmaceuticals
Special Issues
Recent Advances in Cancer Diagnosis and Therapy
share announcement

Recent Advances in Cancer Diagnosis and Therapy

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 30 July 2025 | Viewed by 1001

Special Issue Editors

Dr. Adriana Grigoraș

E-Mail Website
Guest Editor
Department of Histology, University of Medicine and Pharmacy "Gr. T. Popa” Iasi, Iasi, Romania
Interests: obesity-related pathology; tumor pathology; histology
Special Issues, Collections and Topics in MDPI journals
Dr. Hsin-Sheng Yang

E-Mail Website
Guest Editor
Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY, USA
Interests: drug resistance; cancer; signaling pathways; natural products

Special Issue Information

Dear Colleagues,

According to the World Health Organization report, cancer continues to be one of the leading causes of death worldwide. A cancer diagnosis is often made in advanced stages when it is associated with a high risk of recurrence and metastasis. Thus, the early diagnosis of cancer is one the most significant strategies to decrease the cancer mortality rate. Currently, the approach for cancer diagnosis includes non-invasive imaging exams combined with molecular biology techniques and the pathological examination of tissue samples to establish the type and stage of the cancer. In addition, another main cancer-related research priority is to develop new therapeutic tools with a high response rate and limited side-effects.

This Special Issue aims to provide a platform for gathering updated research in cancer-related diagnosis and treatment, which may improve the prognosis of the oncologic patient.

Dr. Adriana Grigoraș
Dr. Hsin-Sheng Yang
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • early diagnosis
  • advanced therapy
  • biomarkers
  • immunohistochemistry
  • molecular diagnosis
  • metastasis
  • prognosis
  • targeted therapies
  • combination therapies
  • cancer pharmacology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

20 pages, 6012 KiB  
Article
Novel Anthraquinone Derivatives and Their Complexes with Metal Ions with Anticancer Activity: Structure/Redox and Chelation Activity Correlations
by Olga Yu. Selyutina, Maya A. Ul’yanova, Olga A. Chinak, Viktor A. Timoshnikov, Lidiya G. Fedenok, Alexander A. Stepanov, Vadim V. Yanshole, Leonid V. Kulik, Sergey F. Vasilevsky, Nikolay E. Polyakov and George J. Kontoghiorghes
Pharmaceuticals 2024, 17(12), 1717; https://doi.org/10.3390/ph17121717 - 19 Dec 2024
Viewed by 670
Abstract
Background/Objectives: Some specific anthraquinone derivatives (AQs) are known to be used widely as effective chemotherapeutic agents in the treatment of cancer. However, their fundamental shortcoming is the high rate of cardiotoxicity observed in treated patients, which is thought to be caused by the [...] Read more.
Background/Objectives: Some specific anthraquinone derivatives (AQs) are known to be used widely as effective chemotherapeutic agents in the treatment of cancer. However, their fundamental shortcoming is the high rate of cardiotoxicity observed in treated patients, which is thought to be caused by the increase in production of reactive oxygen species (ROS) catalyzed by iron and copper. The development of improved AQs and other anticancer drugs with enhanced efficacy but reduced toxicity remains a high priority. The aim of this study was to evaluate the cytotoxic and ROS production effects of chelate iron and copper complexes of two novel AQs, namely 4-hydroxynaphto[2,3-h]cinnoline-7,12-dione (Q2) and 3-(hydroxymethyl)naphto[2,3-h]cinnoline-4,7,12(1H)-trione (Q3). Methods: The chelation ability of Q2 and Q3 was studied using NMR and UV–Vis spectroscopy. Cytotoxicity studies were carried out using the MTT assay. The influence of chelation on ROS production was studied using NMR spectroscopy in linoleic acid micelles. Results: It was found that only Q3 forms complexes with Fe(III) and Cu(II) ions, whereas Q2 does not demonstrate chelating properties. A cytotoxicity study revealed that Fe[Q3]3 significantly decreased the viability of lung cancer A549 cells, while Q3 and Cu[Q3]2 did not demonstrate cytotoxic properties in this cell line. Furthermore, the presence of Q3 lowered the rate of iron-induced lipid peroxidation in linoleic acid micelles. By contrast, Q2 did not influence the rate of lipid peroxidation, probably due to the absence of effective metal chelating ability. Conclusions: The high cytotoxic effects observed with the iron complex of Q3 against cancer cells in combination with a reduced rate of iron induced lipid peroxidation in the presence of Q3, make Q3 and its iron complex promising for further evaluation and use as chemotherapeutic agents in cancer. Full article
(This article belongs to the Special Issue Recent Advances in Cancer Diagnosis and Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop